apixaban
Commercial- Indications
- Cardiovascular disease
Company intelligence / Profile preview
Ultra Medica Pharmaceutical Industries has a commercial-stage portfolio with over approximately two hundred pharmaceutical products spanning oral solids, semi-solids, liquids, and injectables. The company’s drugs address a wide range of therapeutic areas including osteoporosis, mental health disorders such as anxiety and depression, pain management, diabetes mellitus, schizophrenia/psychiatric conditions, cardiac diseases among others. All products are manufactured in compliance with GMP standards for both domestic Syrian market needs and international export requirements.[1][3][4]
3 more assets in the full pipeline.
Request access →Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Ultra Medica Pharmaceutical Industries.